🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Jagsonpal Pharmaceuticals Limited JAGSNPHARM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.jagsonpal.com
Company Profile ↓
₹242.06
-1.30% 1Y
Mkt Cap₹1,620.89 Cr
P/E38.36
P/B5.87
Div. Yield1.68%
52W High₹248.52
52W Low₹158.42
Book Value₹41.24
EPS (TTM)₹6.31

Company Overview

Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 20.3%.

Consistent Profit Growth

Net profit has compounded at 17.3% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 38.4, below the sector median of 41.6.

Healthy Margins

Maintains a net profit margin of 15.0%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹287.23 Cr (+6.9% YoY); net profit ₹43.08 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +6.9%, earnings -22.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 6.7%, profit CAGR 17.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:6.66%
1 Year:6.89%

Compounded Profit Growth

5 Years:17.26%
1 Year:-22.18%

Stock Price Performance

1 Year:-1.30%
6 Months:+41.98%
3 Months:+21.99%
1 Month:+3.39%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 93% of range
₹158.42 ₹248.52
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)62.49 · Neutral
Price Performance
1M+3.39%
3M+21.99%
6M+41.98%
1Y-1.30%
Valuation vs Sector

P/E of 38.36 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 20.3%.
  • Profit CAGR of 17.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
38.36
Industry PE
41.64
Forward P/E est.
49.29
PEG Ratio
-
Book Value
₹41.24
Price to Book
5.87
P/S
5.18
EV/EBITDA
23.01
Dividend Yield
1.68%

Growth (CAGR)

Revenue 5Y
6.66%
Profit 5Y
17.26%
Revenue (YoY)
6.89%
Earnings (YoY)
-22.18%

Profitability & Returns

ROCE
20.30%
ROE
15.60%
ROA
13.60%
Profit Margin
15.00%
Op Margin
16.93%
Gross Margin
63.66%
EPS (Latest Qtr)
₹1.98
EPS (TTM)
₹6.31

Balance Sheet & Liquidity

Debt/Equity
2.96
Quick Ratio
4.54
Current Ratio
5.06
Debt
₹8.16 Cr
Total Assets
₹316.68 Cr
Current Assets
₹143.09 Cr
Working Capital
₹114.79 Cr

Ownership

Promoter Holding
76.06%
Chg in Prom Hold
-0.03%
FII / Inst Holding
2.58%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹1,620.89 Cr
Total Revenue (TTM)
₹287.23 Cr
EBITDA
₹67.99 Cr
Free Cash Flow
₹46.66 Cr
Operating Cash Flow
₹46.81 Cr
Shares Outstanding
₹6.70 Cr
Gross Margin
63.66%
Payout Ratio
37.26%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 JAGSNPHARM Jagsonpal Pharmaceuticals Limited NSEPHARMA 242.06 38.36 ₹1,620.89 Cr 1.68% 20.30% 15.60% 6.66% 17.26%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -58.56 Cr75.61 Cr74.47 Cr72.94 Cr64.20 Cr82.23 Cr
Cost of Revenue -21.72 Cr26.93 Cr27.23 Cr26.45 Cr23.77 Cr28.62 Cr
Gross Profit -36.84 Cr48.69 Cr47.24 Cr46.49 Cr40.44 Cr53.61 Cr
Operating Expenses -30.43 Cr36.83 Cr33.19 Cr32.61 Cr31.60 Cr38.51 Cr
Operating Income -6.41 Cr11.86 Cr14.05 Cr13.88 Cr8.84 Cr15.10 Cr
EBITDA -11.27 Cr17.04 Cr19.46 Cr17.16 Cr14.33 Cr20.07 Cr
Interest Expense -25.90 L25.40 L26.50 L25.70 L25.20 L25.10 L
Pretax Income -8.71 Cr14.43 Cr16.81 Cr14.52 Cr11.76 Cr17.68 Cr
Tax Provision -2.12 Cr3.64 Cr4.24 Cr3.57 Cr2.99 Cr4.49 Cr
Net Income -6.58 Cr10.79 Cr12.57 Cr10.95 Cr8.76 Cr13.19 Cr
Diluted EPS -0.981.581.871.651.211.98

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -236.71 Cr208.70 Cr268.72 Cr287.23 Cr
Cost of Revenue -92.51 Cr79.98 Cr96.44 Cr104.38 Cr
Gross Profit -144.20 Cr128.57 Cr172.28 Cr182.85 Cr
Operating Expenses -109.87 Cr106.96 Cr129.34 Cr134.22 Cr
Operating Income -34.33 Cr21.61 Cr42.94 Cr48.63 Cr
EBITDA -36.26 Cr32.35 Cr78.95 Cr67.99 Cr
Interest Expense -27.80 L77.70 L95.80 L1.03 Cr
Pretax Income -34.81 Cr29.87 Cr69.86 Cr57.52 Cr
Tax Provision -8.09 Cr7.41 Cr14.50 Cr14.44 Cr
Net Income -26.72 Cr22.46 Cr55.36 Cr43.08 Cr
Diluted EPS -4.083.398.226.31

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -194.95 Cr217.08 Cr278.26 Cr316.68 Cr
Current Assets -164.56 Cr196.78 Cr161.19 Cr143.09 Cr
Cash & Equivalents -11.05 Cr12.76 Cr11.21 Cr10.04 Cr
Inventory -20.68 Cr15.00 Cr15.20 Cr14.64 Cr
Receivables -20.87 Cr10.95 Cr13.18 Cr17.19 Cr
Total Liabilities -36.06 Cr29.68 Cr38.31 Cr40.51 Cr
Current Liabilities -27.57 Cr19.13 Cr25.90 Cr28.30 Cr
Long Term Debt 0----
Total Debt -6.00 Cr8.94 Cr9.24 Cr8.16 Cr
Total Equity -158.89 Cr187.40 Cr239.95 Cr276.17 Cr
Shares Outstanding -6.55 Cr6.61 Cr6.64 Cr6.70 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -46.66 Cr35.17 Cr55.11 Cr46.81 Cr
Investing Cash Flow --57.67 Cr-24.55 Cr-45.15 Cr-35.65 Cr
Financing Cash Flow --45.70 L-8.91 Cr-11.70 Cr-12.15 Cr
Capital Expenditure --31.80 L-24.80 L-34.80 L-14.80 L
Free Cash Flow -46.34 Cr34.92 Cr54.77 Cr46.66 Cr
Net Change in Cash --11.47 Cr1.71 Cr-1.73 Cr-98.60 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -60.9%61.6%64.1%63.7%
Operating Margin % -14.5%10.4%16.0%16.9%
Net Margin % -11.3%10.8%20.6%15.0%
ROE % -16.8%12.0%23.1%15.6%
ROCE % -20.5%10.9%17.0%16.9%

Shareholding Pattern

Insiders
76.06%
Institutions
2.58%
Public Float
10.79%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JAGSNPHARM

Google News Mon, 31 Aug 2026

Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) Passed Our Checks, And It's About To Pay A ₹4.00 Dividend - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxOdXQzaDc5LWxyZWVvYXhhREQ2YXFpWS1vRjVOeDQyZ0Z1M2V3SFh6eUFuVTJOUm5sT184WHJmdzIzUnREVmlKNHVxbFBYVkNkTUcwaTV1d2FYVm9DWU81YkxpaXJqTjI2dU0xM0kzODlrTG0wSnVXQkRlQ2RPSWViMWJUSjJmNmhDZFlmNG…

Google News hu, 30 Jul 2026

Volume Gainers, July 30, 2026, 3:30 PM IST: Jagsonpal Pharma Leads - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTE11Y25BVmhsQ3VyNEQ1c0o4NXlqeDhtU3hHMTBGcE1EMXZKT3VUQThIQnB2bUVTZm9McENCSldqVHRlRWlpSGhzdGg4ZHd5TzYxYUxrSlFyZEc1RFFPOEQ5ZnJR?oc=5" target="_blank">Volume Gainers, July 30, 2026, 3:30…

Google News Mon, 08 Jun 2026

Jagsonpharm Faces Headwinds: Stock Declines Amid Pharmaceutical Sector Volatility - Volatility Stop - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQLVRMdGlleEpwSUZOcDd1S0lKS19MbTh5dHZlanhhVlJsNzFaS3NranN6SmdQX2xRWjhnTUlRbHpiTmpJWThyNFZGNTlLQWJpTFN2Vm9mVl9lbi1LNVVpSHFGOHdvbkhRY2JWeDZRa3oxdGlObmdSQ0NiRlhkUHM0cDBEZ1pFSjd5X3JlRT…

Google News hu, 13 Nov 2025

We Think Shareholders Should Be Aware Of Some Factors Beyond Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Profit - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxPRUVpSVJYbnVxRmZiaWw0eDY3YUZFbFhmeFd2RkFqbXUxT1NPMnExZFdFMzBxX1MtcTVHLVhBbDNXRFpSVkJRRmVMODBHUkFYd2ttVXJ2MlFDcUVucTJTQjMtaWZFLXhsNUZTNVVfS0lLWlBSUzlVUlcxZVlsS2NHbC1jd3ZybGVFMlcwcz…

Google News hu, 30 Jul 2026

Jagsonpal Pharmaceuticals Share Price Rises 13.8% Today - Univest

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxObnNWS09tWDZrRTdLRlJrOVFoa016Rk9laS1idWMwOE1SREZ4ZGpBdndDbld1SW1QcldLYzhoYjhZZG5yak0wUWpxcHNYUFNyTDZtZHpYbXdQY2RjQjBXbjh3YmZERGhGelgteWFGZ05QWjRhdlFHWjM2dHJUTjIzYXFESQ?oc=5" targe…

Google News hu, 02 Jul 2026

Jagsonpal Pharmaceuticals (JAGSNPHARM.NS) Holds Near ₹234; Support and Resistance Levels in Focus - Volume Oscillator - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPcEZESXNKc1drdUFxYlZTRzRPNWtLaGtkc3NSSEFILUdYMzQ5a1owM0ZMYXdGSXBEQXMwSTBtN1NpeHBGb1BKSWFmbnJNaFN0emFueEhDb2VJUmRkNHR1QVBudDJ4TldrbUlQU09ObWZUbGQ2RVhGLUt6Y2VWY3FnZDQxMGZzUDFtSEhFcT…

JAGSNPHARM — Frequently Asked Questions

What is the current share price of Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)?

As of 2026-09-08 04:53 IST, Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) trades at ₹242.06 on NSE. Its 52-week range is ₹158.42 to ₹248.52.

What is the market capitalisation of JAGSNPHARM?

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) has a market capitalisation of ₹1,620.89 Cr on NSE.

What is the P/E ratio of JAGSNPHARM?

JAGSNPHARM trades at a trailing price-to-earnings (P/E) ratio of 38.36. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 5.87.

Does JAGSNPHARM pay a dividend?

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) currently offers a dividend yield of 1.68%.

What is the return on equity (ROE) of JAGSNPHARM?

JAGSNPHARM has a return on equity (ROE) of 15.60%. Its return on capital employed (ROCE) is 20.30%.

Is JAGSNPHARM a good stock to buy?

This page provides a data-driven analysis of Jagsonpal Pharmaceuticals Limited (JAGSNPHARM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space